ATF4 and hepatocellular carcinoma: In support, inhibition of the PERK/eIF2α/ATF4/CHOP pathway effectively attenuated sorafenib‐induced TRIB3 upregulation, aligning with previous reports implicating transcription factors ATF4 and CHOP cooperating in the modulation of TRIB3 expression (Figure 2D,E; Figure S2B–E, Supporting Information).[28] Thus, sorafenib operates via a PERK‐related ER stress pathway to trigger TRIB3 in HCC.